Overview of CRISPR/Cas9 and Gene Editing
CRISPR/Cas9 and related protein:RNA complexes are Gene Editing enzymes that are revolutionizing biological research and also starting to enter the therapeutic realm. A Cas9-based therapeutic strategy to treat sickle cell anemia received approval recently in the United Kingdom and is also being considered for FDA approval in the United States.
In this presentation, I will give a broad introduction to enzymes used for Gene Editing, including Cas9, base editors, and prime editors. This introduction is intended for both non-biologists and biologists, including the role of computational analysis in understanding gene editing outcomes.
Date and Time
Location
Hosts
Registration
- Date: 14 Dec 2023
- Time: 06:30 PM to 08:00 PM
- All times are (UTC-05:00) Eastern Time (US & Canada)
-
Add Event to Calendar
- Starts 23 November 2023 08:34 AM
- Ends 14 December 2023 07:00 PM
- All times are (UTC-05:00) Eastern Time (US & Canada)
- No Admission Charge
Speakers
Dr. Pattanayak of Massachusetts General Hospital
Overview of CRISPR/Cas9 and Gene Editing
Biography:
Dr. Vikram (MD/PhD Harvard University) is the Director of Histocompatibility (HLA) Laboratory at the Massachusetts General Hospital and an Instructor in Pathology, Harvard Medical School
You can learn more about his background and contributions through the following links.
Mass General: https://www.massgeneral.org/doctors/20264/vikram-pattanayak
LinkedIn: https://www.linkedin.com/in/vikram-pattanayak-04299b111/
Google Scholar: https://scholar.google.com/citations?user=jlc25hYAAAAJ&hl=en